New review charts a roadmap for biologically informed psychiatric diagnosis using biomarkers and AI.
Key Details
- 1Psychiatric diagnosis still relies on symptom checklists, lacking biological grounding.
- 2Emerging frameworks combine molecular/neuroimaging biomarkers, digital phenotyping, and machine learning integration.
- 3Large consortia (e.g., ENIGMA) tie neuroimaging findings to psychiatric conditions like schizophrenia and depression.
- 4Molecular diagnostic tests (e.g., VeriPsych, EDIT-B) have reached limited clinical adoption; most candidate biomarkers lack clinical utility so far.
- 5AI and multimodal models show promise but face challenges with limited psychiatric datasets, lack of explainability, and real-world validation.
- 6Review emphasizes that objective biological measurement should complement—not replace—clinical judgment.
Why It Matters
For radiology and imaging AI professionals, this review highlights the expanding role of neuroimaging, molecular markers, and AI in mental health, a field historically reliant on subjective measures. Robust integration of imaging and digital phenotyping could reshape diagnosis, steering research and technology development towards actionable and explainable clinical tools.
Source
EurekAlert
Related News
•EurekAlert
Researchers Develop All-Optical Synapse for Neuromorphic Imaging Systems
A new artificial synapse, controlled entirely by light, enables in-sensor neuromorphic processing for more efficient and noise-resistant imaging systems.
•EurekAlert
Mayo Clinic Showcases Imaging AI and Early Cancer Detection Advances at ASCO 2026
Mayo Clinic researchers will present over 30 studies at ASCO 2026, highlighting new advances in imaging AI, data science, and early cancer detection.
•EurekAlert
AI-Simulation Approach Achieves 90% Faster Brain MRI with Minimal Data
A simulation-based AI method can reconstruct brain MRI scans with only 10% of the usual data, greatly reducing scan times.